Finanzen von LB Pharmaceuticals Inc (LBRX)LBRXLB Pharmaceuticals Inc

Evaluating the bottom line, LB Pharmaceuticals Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -75.01%, provide a clear picture of how effectively LBRX converts its operational activities into shareholder value.

In the context of the broader market, LBRX competes directly with industry leaders such as AVLN and LTGO. With a market capitalization of $1.54B, it holds a leading position in the sector. When comparing efficiency, LBRX's gross margin of N/A stands against AVLN's N/A and LTGO's N/A. Such benchmarking helps identify whether LB Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

The company has faced significant net losses, with the latest quarterly net income reported at -51,603,000 USD, and a current ratio of 15.08, indicating good short-term liquidity despite ongoing losses.